BG62068B2 - Хирудинмутеини и техни полиалкиленгликолови конюгати - Google Patents

Хирудинмутеини и техни полиалкиленгликолови конюгати Download PDF

Info

Publication number
BG62068B2
BG62068B2 BG98604A BG9860494A BG62068B2 BG 62068 B2 BG62068 B2 BG 62068B2 BG 98604 A BG98604 A BG 98604A BG 9860494 A BG9860494 A BG 9860494A BG 62068 B2 BG62068 B2 BG 62068B2
Authority
BG
Bulgaria
Prior art keywords
glu
gly
gin
asn
thr
Prior art date
Application number
BG98604A
Other languages
Bulgarian (bg)
English (en)
Inventor
Manfred Kurfuerst
Klaus Ruebsamen
Bernhard Schmied
Wolfgang Koerwer
Juergen Schweden
Hans HOEFFKEN
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62068(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG62068B2 publication Critical patent/BG62068B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Steroid Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicinal Preparation (AREA)
BG98604A 1989-12-01 1994-02-28 Хирудинмутеини и техни полиалкиленгликолови конюгати BG62068B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939800 1989-12-01

Publications (1)

Publication Number Publication Date
BG62068B2 true BG62068B2 (bg) 1999-01-29

Family

ID=6394620

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98604A BG62068B2 (bg) 1989-12-01 1994-02-28 Хирудинмутеини и техни полиалкиленгликолови конюгати

Country Status (9)

Country Link
US (1) US5663141A (ja)
EP (1) EP0502962B1 (ja)
JP (1) JP3187044B2 (ja)
AT (1) ATE135374T1 (ja)
BG (1) BG62068B2 (ja)
CA (1) CA2067224C (ja)
DE (1) DE59010205D1 (ja)
ES (1) ES2084149T3 (ja)
WO (1) WO1991008229A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4117784A1 (de) * 1991-05-31 1992-12-03 Basf Ag Herstellung von protein-polyalkylenglykolkonjugaten
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0663009A1 (en) * 1993-08-04 1995-07-19 Novartis AG High molecular weight desulphatohirudin
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
DE19533817C2 (de) * 1995-09-13 1999-12-09 Max Planck Gesellschaft Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
DE19915862A1 (de) * 1999-04-08 2000-10-12 Max Planck Gesellschaft Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie
US20040228852A1 (en) * 1999-04-08 2004-11-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Use of increased molecular-weight hirudin as an anticoagulant in extracorporeal kidney replace therapy
US6809076B2 (en) * 2000-03-20 2004-10-26 Abbott Gmbh & Co. Kg Use of anticoagulant agents in the extracorporeal treatment of blood
AU2001248355A1 (en) * 2000-03-20 2001-10-03 Knoll Gmbh The use of anticoagulant agents in the extracorporeal treatment of blood
DE10102878A1 (de) * 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
DE10162521A1 (de) * 2001-12-19 2003-07-17 Goetz Nowak Verwendung von molekulargewichtserweiterten Substanzen in der Tumortherapie
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19775033I2 (de) * 1985-04-11 2011-01-20 Bayer Schering Pharma Ag Hirudin-Derivat.
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
FR2628429B1 (fr) * 1988-03-08 1990-12-28 Transgene Sa Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir
AU614121B2 (en) * 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
CA2000887A1 (en) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Thromboresistant materials and methods for making same

Also Published As

Publication number Publication date
CA2067224A1 (en) 1991-06-02
CA2067224C (en) 2001-02-13
JP3187044B2 (ja) 2001-07-11
ES2084149T3 (es) 1996-05-01
EP0502962A1 (de) 1992-09-16
ATE135374T1 (de) 1996-03-15
WO1991008229A1 (de) 1991-06-13
DE59010205D1 (de) 1996-04-18
JPH05503092A (ja) 1993-05-27
EP0502962B1 (de) 1996-03-13
US5663141A (en) 1997-09-02

Similar Documents

Publication Publication Date Title
KR100658961B1 (ko) 공유적으로 가교결합된 인슐린 이량체, 이를 포함하는 약제학적 조성물 및 진단 키트, 및 이의 제조방법
BG62068B2 (bg) Хирудинмутеини и техни полиалкиленгликолови конюгати
US5314872A (en) Glucan sulfate, stabilized fibroblast growth factor composition
US5312736A (en) Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin
FI102843B (fi) Menetelmä oleellisesti puhdistettujen insuliinijohdannaisten valmistam iseksi
US5977310A (en) Peg-modified HGF
US4990455A (en) Novel human TNF polypeptide mutants and DNA's encoding said mutants
AU617291B2 (en) Method of chain combination
BG100420A (bg) Ацилиран инсулин
JPH08506095A (ja) 改変インシュリン様成長因子
EP1575490A2 (en) Modified glucagon-like peptide-1 analogs
KR20000016402A (ko) 렙틴(ob단백질)의 프레그먼트
US7144989B2 (en) Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
JPH06502407A (ja) 血小板凝集阻害剤
US5095004A (en) Fluorine containing atrial natriuretic peptides
JP2669510B2 (ja) ヒルジンのアミノ酸配列に基づくトロンビン阻害剤
US5120715A (en) Method for purifying fibroblast growth factor protein
Tokunaga et al. Synthesis and expression of a human growth hormone (somatotropin) gene mutated to change cysteine‐165 to alanine
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
US5376635A (en) Fluorine containing atrial natriuretic peptides
HU200939B (en) Process for stabilizing htnf obtained by recombinant dna technique
EP0900235B1 (en) Fragments of cr1 and their use
WO2005085283A1 (ja) 修飾インターロイキン−１１及びそれを含有する医薬組成物
JPS63316798A (ja) 新規なペプチド及びこれを有効成分とする創傷治療剤
JPH0817712B2 (ja) 新規ヒトｔｎｆポリペプチド変異体